The estimated Net Worth of Richard King is at least $407 Tausend dollars as of 21 June 2018. Mr King owns over 2,501 units of Spruce Biosciences stock worth over $22,962 and over the last 14 years he sold SPRB stock worth over $63,725. In addition, he makes $320,483 as CEO & Director at Spruce Biosciences.
Mr has made over 2 trades of the Spruce Biosciences stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 2,501 units of SPRB stock worth $63,725 on 21 June 2018.
The largest trade he's ever made was buying 3,500 units of Spruce Biosciences stock on 9 June 2011 worth over $15,960. On average, Mr trades about 500 units every 214 days since 2011. As of 21 June 2018 he still owns at least 48,856 units of Spruce Biosciences stock.
You can see the complete history of Mr King stock trades at the bottom of the page.
Richard A. King M.B.A. is the CEO & Director at Spruce Biosciences.
As the CEO & Director of Spruce Biosciences, the total compensation of Mr A at Spruce Biosciences is $320,483. There are 2 executives at Spruce Biosciences getting paid more, with Dr. Rosh Dias having the highest compensation of $623,441.
Mr A is 56, he's been the CEO & Director of Spruce Biosciences since . There are 1 older and 3 younger executives at Spruce Biosciences. The oldest executive at Spruce Biosciences, Inc. is Michael G. Grey, 68, who is the Exec. Chairman.
Richard's mailing address filed with the SEC is 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, , DALY CITY, CA, 94014.
Over the last 4 years, insiders at Spruce Biosciences have traded over $10,017,426 worth of Spruce Biosciences stock and bought 4,788,400 units worth $38,247,728 . The most active insiders traders include Holdings A/S Novo, Bali Muralidhar und Niall O'donnell. On average, Spruce Biosciences executives and independent directors trade stock every 57 days with the average trade being worth of $210,541. The most recent stock trade was executed by Holdings A/S Novo on 21 March 2024, trading 465,021 units of SPRB stock currently worth $348,766.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Spruce Biosciences executives and other stock owners filed with the SEC include: